[Funding alert] Switzerland-based QUMEA Raises CHF 9Million in Series A Round Funding

The investor group includes Zürcher Kantonalbank (ZKB), PB Invest (Schweiz), two family offices, and a growth loan from UBS.

Read also - Traveltech Company Amadeus Acquired Vision-Box

In addition, this funding round is supported by all existing investors and was significantly oversubscribed. Moreover, the growth loan from UBS underscores the commercial scalability and confidence in QUMEA’s business and company development.

Cyrill Gyger, CEO of QUMEA, on the raising process and outcome: "We are grateful to have had multiple options for this financing round, which is not to be taken for granted in the current funding environment. We chose an investor structure that perfectly aligns with our values and long-term strategy. The trust and continued support of our investor base are invaluable. Now we are perfectly positioned to replicate our Swiss success in international markets."

Yves Becker, Senior Investment Manager at ZKB said, "QUMEA’s technological leadership, its anonymous and precise solution in combination with a consistent and strong business growth, has left a lasting impression on us. I am impressed by QUMEA’s entrepreneurial approach, the exceptional quality of its leadership team, and the team’s unwavering commitment to their guiding principles. Our decision to invest with our scale-up ticket reflects our belief in QUMEA’s extraordinary market-fit and its potential to disrupt an important segment of the healthcare sector."

Andreas Linder, Head of Corporate Clients Solothurn, UBS Switzerland AG: "QUMEA’s traction demonstrates that the company solves an urgent problem in patient care. Being awarded the SEF.Growth High Potential Label in 2023 is additional strong evidence for QUMEA’s potential to scale its business. As a founding partner of the SEF.Growth initiative, UBS is proud to support QUMEA’s continued growth with this loan."

The funds are set to fuel QUMEA’s goal to achieve market leadership in selected international markets. Additionally, the funding will enhance QUMEA’s product strategy, particularly in strengthening and expanding its ‘Software as a Medical Device’ portfolio introduced in 2023, reinforcing its commitment to mission critical decision support.

Read also - Switzerland-based Spiden Secures $15Million in Additional Funding

About QUMEA

QUMEA is transforming care workflows with an intelligent, privacy-respecting mobility monitoring system. The system is used for proactive risk management in hospitals and long-term facilities.

Read also - Stockholm-based Version Lens Secures Pre-Seed Round Funding